NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market on Wednesday that revenues in the fourth quarter increased 13 percent year over year as the firm beat the consensus analyst estimates on the top and bottom lines.

The Mountain View, Calif.-based molecular diagnostic test development firm took in $60.4 million in revenues for the three months ended Dec. 31, 2012, compared to $53.4 million a year ago, topping the average Wall Street estimate of $58.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.